Perspective Therapeutics Expands Alpha-Particle Therapy into Meningiomas — Perspective Therapeutics, Inc.

Event summary

First meningioma patient dosed with [212Pb]VMT-α-NET in Phase 1/2a study on June 3, 2026.
Study expansion targets SSTR2-expressing tumors beyond neuroendocrine tumors (NETs).
Meningiomas represent ~40% of primary brain tumors in the U.S., with limited treatment options for advanced cases.
Interim data from ASCO 2026 showed preliminary efficacy in NET patients; full results pending.

The big picture

Perspective Therapeutics is extending its lead-based alpha-particle therapy into meningiomas, a high-prevalence brain tumor with limited treatment options. This move aligns with broader industry trends toward targeted radiopharmaceuticals, particularly for tumors expressing somatostatin receptors. The company's 'theranostic' approach—combining imaging and therapy—could position it as a key player in precision oncology, provided clinical data supports its expanded use.

What we're watching

Therapeutic Expansion: Whether Perspective can successfully translate [212Pb]VMT-α-NET's efficacy from NETs to meningiomas, a structurally distinct tumor type.
Clinical Data: The pace at which additional efficacy data from Cohort 2 and Cohort 3 patients will be released, particularly for meningioma patients.
Regulatory Pathway: How the FDA may view the expanded use of [212Pb]VMT-α-NET, given its novel mechanism and the unmet need in meningioma treatment.